Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
55
ICCC Quote, Financials, Valuation and Earnings
Last price:
$6.30
Seasonality move
:
10.73%
Day range:
$6.25 - $6.55
52-week range:
$4.52 - $7.60
Dividend yield:
0%
P/E ratio:
32.09x
P/S ratio:
2.10x
P/B ratio:
2.15x
Volume:
6.9K
Avg. volume:
12.5K
1-year change:
18.82%
Market cap:
$57.8M
Revenue:
$27.6M
EPS (TTM):
-$0.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$305.2M | $0.12 | 15.35% | -21.66% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.3B | $2.14 | 88.89% | -58.59% | $449.32 |
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
IDXX
IDEXX Laboratories, Inc.
|
$1.2B | $3.94 | 12.27% | 15.7% | $742.54 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
$6.44 | -- | $57.8M | 32.09x | $0.00 | 0% | 2.10x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
$3.17 | -- | $47.6M | -- | $0.00 | 0% | 1.07x |
|
IDXX
IDEXX Laboratories, Inc.
|
$569.55 | $742.54 | $45.8B | 43.94x | $0.00 | 0% | 10.82x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
-- | 0.756 | -- | 1.61x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
29.04% | -0.878 | 17.2% | 0.81x |
|
IDXX
IDEXX Laboratories, Inc.
|
37.81% | 2.024 | 1.81% | 0.71x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
$2.9M | -$58K | -2.59% | -3.63% | -0.76% | $482.2K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
CPIX
Cumberland Pharmaceuticals, Inc.
|
$10.4M | -$1.3M | -7.51% | -11.11% | -9.77% | -$40.8K |
|
IDXX
IDEXX Laboratories, Inc.
|
$659.5M | $317M | 40.62% | 69.08% | 29.07% | $322.4M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
ImmuCell Corp. vs. Competitors
-
Which has Higher Returns ICCC or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -37.36% compared to ImmuCell Corp.'s net margin of 96.33%. ImmuCell Corp.'s return on equity of -3.63% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.38.16% -$0.32 $27.1M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ICCC or ACAD?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 117.39%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ImmuCell Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ImmuCell Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is ICCC or ACAD More Risky?
ImmuCell Corp. has a beta of 0.302, which suggesting that the stock is 69.846% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock ICCC or ACAD?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or ACAD?
ImmuCell Corp. quarterly revenues are $7.6M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. ImmuCell Corp.'s net income of -$2.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 32.09x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.10x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.2.10x 32.09x $7.6M -$2.8M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns ICCC or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -37.36% compared to ImmuCell Corp.'s net margin of 16.99%. ImmuCell Corp.'s return on equity of -3.63% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.38.16% -$0.32 $27.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ICCC or ALNY?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 117.39%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that ImmuCell Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe ImmuCell Corp. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is ICCC or ALNY More Risky?
ImmuCell Corp. has a beta of 0.302, which suggesting that the stock is 69.846% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock ICCC or ALNY?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or ALNY?
ImmuCell Corp. quarterly revenues are $7.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. ImmuCell Corp.'s net income of -$2.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 32.09x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.10x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.2.10x 32.09x $7.6M -$2.8M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns ICCC or CPIX?
Cumberland Pharmaceuticals, Inc. has a net margin of -37.36% compared to ImmuCell Corp.'s net margin of -10.44%. ImmuCell Corp.'s return on equity of -3.63% beat Cumberland Pharmaceuticals, Inc.'s return on equity of -11.11%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.38.16% -$0.32 $27.1M CPIXCumberland Pharmaceuticals, Inc.76% -$0.09 $34.7M -
What do Analysts Say About ICCC or CPIX?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 117.39%. On the other hand Cumberland Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 168.14%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than ImmuCell Corp., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than ImmuCell Corp..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 CPIXCumberland Pharmaceuticals, Inc.0 0 0 -
Is ICCC or CPIX More Risky?
ImmuCell Corp. has a beta of 0.302, which suggesting that the stock is 69.846% less volatile than S&P 500. In comparison Cumberland Pharmaceuticals, Inc. has a beta of -0.331, suggesting its less volatile than the S&P 500 by 133.113%.
-
Which is a Better Dividend Stock ICCC or CPIX?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cumberland Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Cumberland Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or CPIX?
ImmuCell Corp. quarterly revenues are $7.6M, which are smaller than Cumberland Pharmaceuticals, Inc. quarterly revenues of $13.7M. ImmuCell Corp.'s net income of -$2.8M is lower than Cumberland Pharmaceuticals, Inc.'s net income of -$1.4M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 32.09x while Cumberland Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.10x versus 1.07x for Cumberland Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.2.10x 32.09x $7.6M -$2.8M CPIXCumberland Pharmaceuticals, Inc.1.07x -- $13.7M -$1.4M
-
Which has Higher Returns ICCC or IDXX?
IDEXX Laboratories, Inc. has a net margin of -37.36% compared to ImmuCell Corp.'s net margin of 22.76%. ImmuCell Corp.'s return on equity of -3.63% beat IDEXX Laboratories, Inc.'s return on equity of 69.08%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.38.16% -$0.32 $27.1M IDXXIDEXX Laboratories, Inc.60.47% $3.08 $2.6B -
What do Analysts Say About ICCC or IDXX?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 117.39%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $742.54 which suggests that it could grow by 30.37%. Given that ImmuCell Corp. has higher upside potential than IDEXX Laboratories, Inc., analysts believe ImmuCell Corp. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 IDXXIDEXX Laboratories, Inc.5 5 0 -
Is ICCC or IDXX More Risky?
ImmuCell Corp. has a beta of 0.302, which suggesting that the stock is 69.846% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.722, suggesting its more volatile than the S&P 500 by 72.194%.
-
Which is a Better Dividend Stock ICCC or IDXX?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or IDXX?
ImmuCell Corp. quarterly revenues are $7.6M, which are smaller than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. ImmuCell Corp.'s net income of -$2.8M is lower than IDEXX Laboratories, Inc.'s net income of $248.2M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 32.09x while IDEXX Laboratories, Inc.'s PE ratio is 43.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.10x versus 10.82x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.2.10x 32.09x $7.6M -$2.8M IDXXIDEXX Laboratories, Inc.10.82x 43.94x $1.1B $248.2M
-
Which has Higher Returns ICCC or SVRA?
Savara, Inc. has a net margin of -37.36% compared to ImmuCell Corp.'s net margin of --. ImmuCell Corp.'s return on equity of -3.63% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.38.16% -$0.32 $27.1M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About ICCC or SVRA?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 117.39%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that ImmuCell Corp. has higher upside potential than Savara, Inc., analysts believe ImmuCell Corp. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 SVRASavara, Inc.6 0 0 -
Is ICCC or SVRA More Risky?
ImmuCell Corp. has a beta of 0.302, which suggesting that the stock is 69.846% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock ICCC or SVRA?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or SVRA?
ImmuCell Corp. quarterly revenues are $7.6M, which are larger than Savara, Inc. quarterly revenues of --. ImmuCell Corp.'s net income of -$2.8M is higher than Savara, Inc.'s net income of -$32.2M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 32.09x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.10x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.2.10x 32.09x $7.6M -$2.8M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
